GSK on COVID and vaccine development: the pharmaphorum podcast
In the latest episode of the pharmaphorum podcast Dominic Tyer speaks with GlaxoSmithKline’s Philip Cruz about the discovery and commercialisation of new vaccines in the light of the pandemic.
Philip who is vaccines medical director for the UK and Ireland, and a paediatrician by training, tackles the clear pre- and post-COVID differentiation seen in approaches to vaccines.
They also talk about the impact anti-vaxx misinformation has had on vaccine uptake in recent years and what impact COVID has had on that.
Philip also discusses GSK’s recent mRNA vaccine research deal with CureVac, a pact that will see them collaborate on vaccines and monoclonal antibody research programmes in infectious diseases.
You can listen to episode 33 of the pharmaphorum podcast in the player below, download the episode to your computer or find it – and subscribe to the rest of the series in iTunes, Spotify, acast, Stitcher and Podbean.
